Education and Training
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Fostamatinib 150 mg
- drug: Fostamatinib 100 mg
- drug: Placebo
Eligibility
Inclusion Criteria:
- Renal biopsy findings consistent with IgA nephropathy
- Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin
II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated)
dose
- Proteinuria > 1 gm/day at diagnosis of IgA nephropathy and Proteinuria > 0.50 gm/day
at the second Screening Visit
- Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other
anti-hypertensive agents
Exclusion Criteria:
- Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab.
- Use of > 15 mg/day prednisone (or other corticosteroid equivalent).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard Lafayette, MD
650-498-6063
Not Recruiting